Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Top-line Phase 2a Data from Etokimab (ANB020) in Eosinophilic Asthma Expected in Third Quarter of 2018Etokimab Clinical Development Program Expanded to Include Chronic Rhinosinusitis with Nasal...
-
SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
-
SAN DIEGO, May 30, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
-
Blood eosinophil level reduction consistent with clinical efficacy in ANB020 Phase 2a atopic dermatitis trialANB020-mediated eosinophil reduction is aligned with genotypic data from prior human IL-33...
-
Positive Phase 2a Proof-of-Concept Data Reported from ANB020 Trials in Atopic Dermatitisand Peanut Allergy Top-Line Phase 2a Data from ANB020 in Eosinophilic Asthma Expected in the Third Quarter of...
-
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
-
SAN DIEGO, April 27, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
-
46% of adult peanut allergy patients with moderate-to-severe baseline symptoms tolerated 500mg cumulative peanut challenge at 14 days after a single dose of ANB020 compared to zero percent dosed with...
-
ANB020 Top-Line Phase 2a Readouts Anticipated For Peanut Allergy in March 2018 and Eosinophilic Asthma in Second Quarter 2018 ANB019 GPP and PPP Phase 2 Studies to be Initiated...
-
SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...